Corporate Banner
Satellite Banner
Biomolecular Screening
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Taking Special Care of Dangerous Pathogens with Tecan’s Infinite® 200 PRO

Published: Monday, September 24, 2012
Last Updated: Monday, September 24, 2012
Bookmark and Share
Tecan’s Infinite® 200 PRO is a simple to use, convenient size and a robust device.

The P4 Inserm-Jean Mérieux laboratory in Lyon is Europe’s largest high security pathogen laboratory, and relies on the flexibility, robustness and reliability of Tecan’s Infinite® 200 PRO monochromator-based microplate reader for use with Risk Group 4 pathogens including the Ebola, Marburg, Lassa, Nipah and Hendra viruses.

Stéphane Mely, Biological Technics Engineer in the in vitro experimentation and diagnostic team at P4, explained: “We chose the Infinite 200 PRO specifically for absorbance-, luminescence- and fluorescence-based assays performed in accordance with very special BSL4 conditions. These include ELISAs, bioluminescence detection using luciferase activity, and pathogen detection with molecules coupled with fluorophores.”

“One of the most important aspects of equipment in a Category 4 laboratory is robustness, not least because of limited access to the laboratory for maintenance and repairs. The Infinite 200 PRO’s resistance to decontamination products such as hydrogen peroxide is essential for our work, and its monochromator system allows us to work with any wavelength we need, without considering whether or not we have the correct filters. It is simple to use, a convenient size and, like all Tecan instruments, is known to be a robust device.”


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,200+ scientific posters on ePosters
  • More than 4,800+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Tecan and TAP Biosystems Announces a Co-Marketing Agreement
Companies to automate RAFT™ 3D cell culturing on the Freedom EVO®.
Thursday, November 01, 2012
Tecan Award 2011 Winner Announced
Svenja Kristina Holle from UHM has won 2011 award.
Friday, February 24, 2012
Tecan and Artel Partner to Offer QC Kit
QC Kit - a fully integrated performance verification solution for Freedom EVO® workstations.
Tuesday, February 07, 2012
Tecan Launches new Services for Australasia
New business venture aimed at providing regional support to Tecan customers throughout in Australia, New Zealand and the Pacific islands.
Friday, March 12, 2010
Scientific News
Liquid Biopsies: Miracle Diagnostic or Next New Fad?
Thanks to the development of highly specific gene-amplification and sequencing technologies liquid biopsies access more biomarkers relevant to more cancers than ever before.
Drug Candidates Reduce Abnormal Protein Production
New drug candidates improve cell ability to catch miss-folded proteins that could cause deadly diseases.
Supercomputing and Drug Discovery
New biotech company uses supercomputer simulations to speed up drug discovery and biotech molecule development.
Preventing Breast Cancer with Hops
Study of hops extract suggests prevention of breast cancer through chemical pathway activation.
Treatment Advancement for Gaucher and Parkinson's Diseases
NIH scientists identify molecule that may act as a possible treatment of neurological diseases.
Biomunex Confirms Optimal Properties and Activity of BiXAb® Antibodies
Biomunex‘s Plug-and-Play bispecific antibodies demonstrated excellent in vitro properties and in vivo activity positively differentiating their BiXAb platform from competing formats.
Liquid Biopsy Predicts Colon Cancer Recurrence
Scientists have used a genetic test that spots bits of cancer-related DNA circulating in the blood to accurately predict the likelihood of the disease’s return in some — but not all — of a small group of patients with early-stage colon cancer.
New Treatment for Rare Blood Cancers
Drug called midostaurin showed promise in an international clinical trial led by a Stanford physician.
Biomarker for Parkinson's Disease Found in Urine Samples
Protein identified as Parkinson's biomarker sourced from patient's stored frozen urine samples.
Testing for Malaria or Cancer at Home
Chemist develops tech to save lives in rural Africa.
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,200+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,800+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!